Karen Akinsanya - Feb 9, 2022 Form 4 Insider Report for Schrodinger, Inc. (SDGR)

Role
EVP, Chief Biomedical Scientist, Head of Discovery R&D
Signature
/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
Stock symbol
SDGR
Transactions as of
Feb 9, 2022
Transactions value $
$0
Form type
4
Date filed
2/9/2022, 08:14 PM
Previous filing
Oct 19, 2021
Next filing
Mar 31, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SDGR Stock Option (right to buy) Award $0 +80K $0.00 80K Feb 9, 2022 Common Stock 80K $27.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 9, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 9, 2023 and the remainder are scheduled to vest in equal monthly installments through February 9, 2026.

Remarks:

EVP, Chief Biomedical Scientist, Head of Discovery R&D